HealthPolitics

STAT+: HHS plans funding for research into ibogaine for PTSD

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 14/11/2026, 10:07:24 UTC.

Briefings

A biotech newsletter subscription page from 2026 discusses a potential acquisition where Oura, a smart ring maker, plans to buy Counsel Health, a telehealth company. This acquisition would give Oura a financial stake in Lilly, which promotes GLP-1 telehealth services. The article notes that Lilly has agreed to buy $50 million in Oura stock but states the conditions for this deal have not yet been met.

Key points

• Oura plans to acquire Counsel Health, a telehealth company, for a $50 million stock purchase.
• This acquisition would give Oura a financial interest in Lilly, which promotes GLP-1 telehealth services.

Context

This finding relates to biotech industry consolidation, specifically the potential merger of smart device maker Oura with a telehealth firm. The acquisition would create a financial link between Oura and Lilly, which markets GLP-1 telehealth solutions.

Limitations

Evidence is limited to a newsletter subscription page from 2026. No specific dates, locations, or named individuals are provided. The article does not confirm the acquisition has occurred, only that it is under discussion. The conditions for the $50 million stock purchase remain unmet.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 14/11/2026, 10:44:32 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeid26cchywnb77h72fedk3emv2keacqfurecj2ss6led7ly5lsneyi